Standard BioTools Inc. reported third quarter 2025 revenue of $46.2 million, with $19.6 million from continuing operations. The company implemented a restructuring plan for over $40 million in annual cost savings and aims for positive adjusted EBITDA in 2026. With $217 million in cash as of September 30, 2025, and $550 million expected from a transaction with Illumina in 2026, Standard BioTools is well-positioned for growth. The company also consolidated operations into a new headquarters in Boston. Financial results show a net loss of $31.7 million in Q3 2025 and $16.5 million adjusted EBITDA loss.

Revenue for Standard BioTools in the third quarter of 2025 was $19.6 million, down 11% year-over-year. Gross margins were approximately 48.5%, with $217 million in cash and cash equivalents as of September 30, 2025. The company continues to expect revenue in the range of $165 million to $175 million for fiscal year 2025. Standard BioTools provided reconciliations of GAAP to non-GAAP financial information, including gross profit, operating expenses, and adjusted EBITDA for both continuing and discontinued operations. The company’s financial outlook remains strong despite challenges in the operating environment.

Read more at GlobeNewswire: Standard BioTools Reports Third Quarter 2025 Financial